Page last updated: 2024-10-27
fenofibrate and Local Neoplasm Recurrence
fenofibrate has been researched along with Local Neoplasm Recurrence in 1 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors." | 2.79 | A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Robison, NJ | 1 |
| Campigotto, F | 1 |
| Chi, SN | 1 |
| Manley, PE | 1 |
| Turner, CD | 1 |
| Zimmerman, MA | 1 |
| Chordas, CA | 1 |
| Werger, AM | 1 |
| Allen, JC | 1 |
| Goldman, S | 1 |
| Rubin, JB | 1 |
| Isakoff, MS | 1 |
| Pan, WJ | 1 |
| Khatib, ZA | 1 |
| Comito, MA | 1 |
| Bendel, AE | 1 |
| Pietrantonio, JB | 1 |
| Kondrat, L | 1 |
| Hubbs, SM | 1 |
| Neuberg, DS | 1 |
| Kieran, MW | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500] | Phase 2 | 101 participants (Actual) | Interventional | 2005-01-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
27-Week Overall Survival
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.61 |
27-Week Progression-Free Survival
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.31 |
Therapy Completion Rate
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks
| Intervention | proportion of patients (Number) |
|---|
| 5-drug Metronomic Antiangiogenic Regimen | .25 |
Best Response
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.
| Intervention | participants (Number) |
|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable |
|---|
| 5-drug Metronomic Antiangiogenic Regimen | 1 | 12 | 36 | 47 | 1 |
Trials
1 trial available for fenofibrate and Local Neoplasm Recurrence